Clinical Trials Logo

Clinical Trial Summary

The Vancomycin Study is a multi-center, prospective randomized controlled trial that will compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder at the time of fracture fixation.


Clinical Trial Description

Primary Aim: Compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder. Primary Hypothesis: The proportion of deep surgical site infections will be lower for patients treated with local Vancomycin powder. Secondary Aim #1: Compare antibiotic sensitivities of the bacteria in the patients who develop deep surgical site infections in study patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder. Hypothesis 1: In the patients who develop infections, the antibiotic sensitivity profiles between patients treated with local Vancomycin powder will be non-inferior to those treated without local Vancomycin powder. Secondary Aim #2: Build and validate a risk prediction model for the development of deep surgical site infections in patients treated without local Vancomycin powder. (b) Explore whether the effect of local Vancomycin powder is modified by the predicted risk of infection. Hypothesis 2: Patient (e.g. medical co-morbidities) and injury (e.g open fractures) factors will be highly predictive of infection risk. Hypothesis 3: Patients with higher predictive risk will experience greater benefit from local antibiotics. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02227446
Study type Interventional
Source Major Extremity Trauma Research Consortium
Contact
Status Completed
Phase Phase 3
Start date October 2014
Completion date November 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04678154 - Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT Phase 3
Recruiting NCT04597008 - Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA Phase 3
Completed NCT01798810 - Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery N/A